| Doxorubicin (DOX) drug |
Cancer therapy |
Hyperthermia-induced cell
death |
Sustained drug
release and
reduced side effects |
(3) |
| Plasmid DNA |
Gene delivery |
Transfection |
Cations help to improve
the transfection process |
(7) |
| BMD drug |
Anti-inflammatory |
Absorption to the deeper
layers |
Effective
drug penetration
and accumulation in the epidermis |
(11) |
| A1 peptide |
Cancer therapy |
Cause rapid leakage of cytoplasmic
contents |
Cytotoxic
to cancer cells |
(12) |
| PTX drug |
Cancer therapy |
Enhance polymerization of
tubulin |
Reduce side
effects and
improve its therapeutic index |
(14) |
| Phenol
(recovered from olive
mill waste) |
Antioxidant |
Inhibit cell damage |
High stability, sustained
drug release |
(21) |
| Insulin |
Diabetes treatment |
Reduce blood glucose levels |
Stable in simulated gastrointestinal
tract conditions, poor permeability of the intestinal epithelium |
(22) |
| BSA |
Vaccine therapy |
Stimulated proliferation
of CD8+ T cells |
Modulate primary, long-term,
and/or innate immunity, impacting adjuvant choice for vaccine design |
(26) |
| BSA/cholera toxin B subunits |
Vaccine delivery |
Increased antibody production |
Better humoral immune response |
(28) |
